Table 1.

Frequency (%) of CHD genetic alterations and expression levels in 960 TCGA breast cancers

Gene	Location	DNA alterations						mRNA expression levels
		Amp	Gain	Diploid	Hetloss	Homdel	Mutation	Z score ≥ 1	1 > Z score > −1	Z score ≤ −1
CHD1	5q15‐q21	0.21	18.13	55.83	25.00	0.83	0.63	8.44	89.79	1.77
CHD2	15q26	3.54	13.75	57.60	25.00	0.10	0.94	11.35	69.58	19.06
CHD3	17p13.1	0.10	5.42	33.44	60.31	0.73	1.46	6.25	58.65	35.10
CHD4	12p13	3.33	21.88	60.42	14.17	0.21	2.08	19.27	64.58	16.15
CHD5	1p36.31	0.73	6.56	53.23	38.85	0.63	1.46	1.67	98.33	0.00
CHD6	20q12	1.98	40.10	51.35	6.46	0.10	1.98	21.04	64.79	14.17
CHD7	8q12.2	8.85	44.06	41.25	5.73	0.10	1.25	33.96	55.31	10.73
CHD8	14q11.2	0.63	17.40	59.79	22.08	0.10	1.46	17.92	60.00	22.08
CHD9	16q12.2	1.88	12.60	29.38	55.10	1.04	1.46	9.58	71.88	18.54

Amp, high‐level amplification; Gain, low‐level gain; Hetloss, heterozygous deletion; Homdel, homozygous deletion. Numbers in bold indicate higher frequencies of DNA or mRNA alternations (Amp > 5%; Gain and Hetloss > 35%, and mRNA (Z score) up‐ or down‐regulation  >30%).